{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:59:34Z","timestamp":1793854774944,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fighting breast tumors mandates finding different agents devoid of chemotherapy side effects. Repurposing existing drugs, such as statins, presents a promising avenue for the development of novel cancer therapeutics. Based on the different effects of statin members, this study aims to evaluate the effect of two of the most promising lipophilic statins, Simvastatin and Pitavastatin, and their combination with a conventional chemotherapeutic regimen of doxorubicin and cyclophosphamide on breast cancer cells. MDA-MB-231 and MCF7 cell lines were used to analyze the effects of Pitavastatin and simvastatin in combination with doxorubicin\/cyclophosphamide. Cell viability and cell cycle were analyzed and certain apoptosis-related genes such as Bax, Bcl2, and caspase-3, besides cyclin D1 were analyzed using qPCR. The viability of breast cancer cells decreased significantly after treatment with a doxorubicin\/cyclophosphamide combination in the presence of Pitavastatin or simvastatin compared with dual doxorubicin\/cyclophosphamide with a higher effect in MDA-MB-231 cells than MCF7. In MDA-MB-231, The triple combination of Pitavastatin or simvastatin with doxorubicin\/cyclophosphamide resulted in an increase in the expression levels of apoptotic markers than treatment with doxorubicin\/cyclophosphamide combination (Bax (p-value\u2009=\u20090.09&amp; 0.02, respectively), Bax\/Bcl2 ratio (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.0002&amp; &lt;0.0001, respectively)). However, the increase in caspase3 wasn\u2019t significant (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.45&amp; 0.09, respectively). Moreover, the expression of cyclin D1 decreased (<jats:italic>p<\/jats:italic>-value\u2009=\u20090.0002&amp; &lt;0.0001, respectively) and the cell cycle was arrested in the G1 phase. Combination of Pitavastatin or simvastatin with doxorubicin\/ cyclophosphamide may induce apoptosis in breast cancer cells via upregulation of the Bax\/Bcl2 pathway, potentially providing a promising new therapeutic strategy for breast cancer.<\/jats:p>","DOI":"10.1007\/s12032-023-02248-7","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T09:02:41Z","timestamp":1701766961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Enhanced therapeutic efficacy of doxorubicin\/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Samar A.","family":"Dewidar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-4207","authenticated-orcid":false,"given":"Omar","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moetaza M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"El Gayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Mesery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"issue":"3","key":"2248_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, et al. Cancer statistics for African American\/Black people 2022. CA Cancer J Clin. 2022;72(3):202\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2248_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2248_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106.","journal-title":"Genes Dis"},{"key":"2248_CR4","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz S et al. Breast Cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment Strategies-An updated review. Cancers (Basel), 2021. 13(17).","DOI":"10.3390\/cancers13174287"},{"issue":"8","key":"2248_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2174\/1570163817666200518081955","volume":"20","author":"MA Mir","year":"2020","unstructured":"Mir MA, et al. Targeting different pathways using Novel Combination Therapy in Triple negative Breast Cancer. Curr Cancer Drug Targets. 2020;20(8):586\u2013602.","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"2248_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary Breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431\u20139.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2248_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive Breast cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"12","key":"2248_CR8","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G von Minckwitz","year":"2005","unstructured":"von Minckwitz G, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable Breast cancer: the GEPARDUO study of the German breast Group. J Clin Oncol. 2005;23(12):2676\u201385.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2248_CR9","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, et al. Weekly paclitaxel in the adjuvant treatment of Breast cancer. N Engl J Med. 2008;358(16):1663\u201371.","journal-title":"N Engl J Med"},{"issue":"5","key":"2248_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.6004\/jnccn.2021.0023","volume":"19","author":"WJ Gradishar","year":"2021","unstructured":"Gradishar WJ, et al. NCCN Guidelines\u00ae insights: Breast Cancer, Version 4.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(5):484\u201393.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2248_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CEJ.0000000000000497","volume":"28","author":"Y Kobayashi","year":"2019","unstructured":"Kobayashi Y, et al. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? Eur J Cancer Prev. 2019;28(6):562\u20137.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"2248_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","volume":"19","author":"G Jin","year":"2014","unstructured":"Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014;19(5):637\u201344.","journal-title":"Drug Discov Today"},{"issue":"1","key":"2248_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12915-021-00972-y","volume":"19","author":"DA Ammendolia","year":"2021","unstructured":"Ammendolia DA, Bement WM, Brumell JH. Plasma membrane integrity: implications for health and Disease. BMC Biol. 2021;19(1):71.","journal-title":"BMC Biol"},{"issue":"1","key":"2248_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13578-021-00579-4","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W, Liu Y, Zhang H. Extracellular matrix: an important regulator of cell functions and skeletal muscle development. Cell & Bioscience. 2021;11(1):65.","journal-title":"Cell & Bioscience"},{"key":"2248_CR15","doi-asserted-by":"publisher","first-page":"682911","DOI":"10.3389\/fonc.2021.682911","volume":"11","author":"I Giacomini","year":"2021","unstructured":"Giacomini I, et al. Cholesterol metabolic reprogramming in Cancer and its pharmacological modulation as therapeutic strategy. Front Oncol. 2021;11:682911.","journal-title":"Front Oncol"},{"key":"2248_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/LPI.S37450","volume":"9","author":"JT Davies","year":"2016","unstructured":"Davies JT, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13\u201329.","journal-title":"Lipid Insights"},{"key":"2248_CR17","doi-asserted-by":"crossref","unstructured":"Tilija Pun N, Jeong CH. Statin as a potential Chemotherapeutic Agent: current updates as a Monotherapy, Combination Therapy, and treatment for Anti-cancer Drug Resistance. Pharmaceuticals (Basel), 2021. 14(5).","DOI":"10.3390\/ph14050470"},{"issue":"12","key":"2248_CR18","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.bcp.2013.04.009","volume":"85","author":"K Wu","year":"2013","unstructured":"Wu K, et al. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem Pharmacol. 2013;85(12):1753\u201360.","journal-title":"Biochem Pharmacol"},{"key":"2248_CR19","doi-asserted-by":"crossref","unstructured":"Duarte JA, de Barros ALB, Leite EA. The potential use of simvastatin for cancer treatment: a review. Volume 141. Biomedicine & Pharmacotherapy; 2021. p. 111858.","DOI":"10.1016\/j.biopha.2021.111858"},{"issue":"8","key":"2248_CR20","first-page":"3797","volume":"17","author":"S Bhargavi","year":"2016","unstructured":"Bhargavi S, et al. Purification of Lovastatin from Aspergillus terreus (KM017963) and evaluation of its anticancer and antioxidant properties. Asian Pac J Cancer Prev. 2016;17(8):3797\u2013803.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"42","key":"2248_CR21","doi-asserted-by":"publisher","first-page":"72147","DOI":"10.18632\/oncotarget.20046","volume":"8","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi Y, et al. Drug repositioning of mevalonate pathway inhibitors as antitumor agents for Ovarian cancer. Oncotarget. 2017;8(42):72147\u201356.","journal-title":"Oncotarget"},{"issue":"1","key":"2248_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","volume":"19","author":"BA Hamelin","year":"1998","unstructured":"Hamelin BA, Turgeon J. Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26\u201337.","journal-title":"Trends Pharmacol Sci"},{"key":"2248_CR23","doi-asserted-by":"publisher","first-page":"13201","DOI":"10.2147\/OTT.S283033","volume":"13","author":"M Bytautaite","year":"2020","unstructured":"Bytautaite M, Petrikaite V. Comparative study of lipophilic statin activity in 2D and 3D in vitro models of human Breast Cancer cell lines MDA-MB-231 and MCF-7. OncoTargets and Therapy. 2020;13:13201\u20139.","journal-title":"OncoTargets and Therapy"},{"issue":"10","key":"2248_CR24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.jsps.2022.07.011","volume":"30","author":"SA Dewidar","year":"2022","unstructured":"Dewidar SA, et al. Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in Breast cancer patients: a randomized controlled clinical trial. Saudi Pharm J. 2022;30(10):1486\u201396.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"2248_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02889282","volume":"24","author":"LL Vindelov","year":"1977","unstructured":"Vindelov LL. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei. Virchows Arch B Cell Pathol. 1977;24(3):227\u201342.","journal-title":"Virchows Arch B Cell Pathol"},{"issue":"9","key":"2248_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","volume":"8","author":"B Fisher","year":"1990","unstructured":"Fisher B, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node Breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical adjuvant breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483\u201396.","journal-title":"J Clin Oncol"},{"key":"2248_CR27","doi-asserted-by":"crossref","unstructured":"Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes Int J Breast Cancer, 2013. 2013: p.\u00a0137414.","DOI":"10.1155\/2013\/137414"},{"issue":"1","key":"2248_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","volume":"20","author":"CH Beckwitt","year":"2018","unstructured":"Beckwitt CH, et al. Statin Drugs to reduce Breast cancer recurrence and mortality. Breast cancer Research: BCR. 2018;20(1):144\u20134.","journal-title":"Breast cancer Research: BCR"},{"issue":"4","key":"2248_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/joim.12806","volume":"284","author":"S Borgquist","year":"2018","unstructured":"Borgquist S, et al. Statins: a role in Breast cancer therapy? J Intern Med. 2018;284(4):346\u201357.","journal-title":"J Intern Med"},{"key":"2248_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/VHRM.S306540","volume":"17","author":"D Nagayama","year":"2021","unstructured":"Nagayama D, Saiki A, Shirai K. The Anti-cancer Effect of Pitavastatin May be a drug-specific effect: Subgroup Analysis of the TOHO-LIP study. Vasc Health Risk Manag. 2021;17:169\u201373.","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"2248_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-014-3192-3","volume":"148","author":"D Balmativola","year":"2014","unstructured":"Balmativola D, et al. Pathological non-response to chemotherapy in a neoadjuvant setting of Breast cancer: an inter-institutional study. Breast Cancer Res Treat. 2014;148(3):511\u201323.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"2248_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-022-01733-9","volume":"39","author":"S O\u2019Grady","year":"2022","unstructured":"O\u2019Grady S, Crown J, Duffy MJ. Statins inhibit proliferation and induce apoptosis in triple-negative Breast cancer cells. Med Oncol. 2022;39(10):142.","journal-title":"Med Oncol"},{"issue":"S1","key":"2248_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.31557\/APJCP.2021.22.S1.33","volume":"22","author":"A Rezano","year":"2021","unstructured":"Rezano A, et al. Cytotoxicity of simvastatin in human Breast Cancer MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev. 2021;22(S1):33\u201342.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"2248_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12609-014-0144-1","volume":"6","author":"BC Litzenburger","year":"2014","unstructured":"Litzenburger BC, Brown PH. Advances in preventive therapy for estrogen-receptor-negative Breast Cancer. Curr Breast Cancer Rep. 2014;6(2):96\u2013109.","journal-title":"Curr Breast Cancer Rep"},{"key":"2248_CR35","doi-asserted-by":"publisher","first-page":"574068","DOI":"10.3389\/fphar.2020.574068","volume":"11","author":"L Yin","year":"2020","unstructured":"Yin L, et al. Simvastatin suppresses human Breast Cancer Cell Invasion by decreasing the expression of pituitary tumor-transforming gene 1. Front Pharmacol. 2020;11:574068.","journal-title":"Front Pharmacol"},{"issue":"23","key":"2248_CR36","doi-asserted-by":"publisher","first-page":"19516","DOI":"10.1074\/jbc.M111.337428","volume":"287","author":"CH Yoon","year":"2012","unstructured":"Yoon CH, et al. PTTG1 oncogene promotes Tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem. 2012;287(23):19516\u201327.","journal-title":"J Biol Chem"},{"issue":"3","key":"2248_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-017-4294-5","volume":"164","author":"C Ahlin","year":"2017","unstructured":"Ahlin C, et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat. 2017;164(3):667\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2248_CR38","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.3892\/ol.2017.6736","volume":"14","author":"YS Shan","year":"2017","unstructured":"Shan YS, et al. Cyclin D1 overexpression correlates with poor Tumor differentiation and prognosis in gastric cancer. Oncol Lett. 2017;14(4):4517\u201326.","journal-title":"Oncol Lett"},{"issue":"1","key":"2248_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/pr.111.004994","volume":"64","author":"P Gazzerro","year":"2012","unstructured":"Gazzerro P, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64(1):102\u201346.","journal-title":"Pharmacol Rev"},{"key":"2248_CR40","doi-asserted-by":"crossref","unstructured":"Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.","DOI":"10.1186\/1756-9966-30-87"},{"key":"2248_CR41","doi-asserted-by":"crossref","unstructured":"Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett. 2017;14(5):6243\u201350.","DOI":"10.3892\/ol.2017.6783"},{"key":"2248_CR42","doi-asserted-by":"crossref","unstructured":"Wang ST, Ho HJ, Lin JT, Shieh JJ, Wu CY. Simvastatin-induced cell cycle arrest through inhibition of STAT3\/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8(2):e2626.","DOI":"10.1038\/cddis.2016.472"},{"key":"2248_CR43","doi-asserted-by":"crossref","unstructured":"Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17(1):88\u201394.","DOI":"10.1158\/1055-9965.EPI-07-0531"},{"key":"2248_CR44","doi-asserted-by":"crossref","unstructured":"Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26(5):883\u201391.","DOI":"10.1093\/carcin\/bgi036"},{"key":"2248_CR45","doi-asserted-by":"crossref","unstructured":"Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208\u201312.","DOI":"10.1152\/ajpcell.00226.2006"},{"key":"2248_CR46","doi-asserted-by":"crossref","unstructured":"Fromigu\u00e9 O, Ha\u00ff E, Modrowski D, Bouvet S, Jacquel A, Auberger P, et al. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42\/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006;13(11):1845\u201356.","DOI":"10.1038\/sj.cdd.4401873"},{"key":"2248_CR47","doi-asserted-by":"crossref","unstructured":"Ahmadi Y, Ghorbanihaghjo A, Argani H. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms. Chem Biol Interact. 2017;273:273\u201385.","DOI":"10.1016\/j.cbi.2017.06.026"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02248-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T10:16:24Z","timestamp":1704708984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02248-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2248"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02248-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee of the Faculty of Pharmacy, Mansoura University (Ref. No. 2020\u2009\u2212\u2009176) approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"All authors declare they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}